Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
K Shiraki, N Sato, K Sakai, S Matsumoto… - Pharmacology & …, 2022 - Elsevier
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …
APASL consensus statements and management algorithms for hepatitis C virus infection
M Omata, T Kanda, ML Yu, O Yokosuka, SG Lim… - Hepatology …, 2012 - Springer
Abstract The Asian Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL Consensus Statements and Management …
international working party on the “APASL Consensus Statements and Management …
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a …
M Manns, P Marcellin, F Poordad, ESA De Araujo… - The Lancet, 2014 - thelancet.com
Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were
the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained …
the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained …
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C
P Marcellin, X Forns, T Goeser, P Ferenci, F Nevens… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Recent studies have shown that 12 weeks of treatment with
telaprevir, administered every 8 hours (q8h), combined with pegylated interferon …
telaprevir, administered every 8 hours (q8h), combined with pegylated interferon …
[HTML][HTML] Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model
The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a
standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and …
standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and …
[HTML][HTML] Chronic hepatitis C treatment outcomes in low-and middle-income countries: a systematic review and meta-analysis
N Ford, C Kirby, K Singh, EJ Mills… - Bulletin of the World …, 2012 - SciELO Public Health
OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in
low-and middle-income countries and identify factors associated with successful outcomes …
low-and middle-income countries and identify factors associated with successful outcomes …
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and …
Background. A systematic review and meta-analysis were conducted to examine the efficacy
and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) …
and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) …
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon
J Levitsky, MI Fiel, JP Norvell, E Wang, KD Watt… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: Patients with recurrent hepatitis C virus infection treated with
pegylated interferon (PEG) after liver transplantation can develop severe immune-mediated …
pegylated interferon (PEG) after liver transplantation can develop severe immune-mediated …
[HTML][HTML] Peginterferon and ribavirin treatment for hepatitis C virus infection
A Tsubota, K Fujise, Y Namiki… - World journal of …, 2011 - ncbi.nlm.nih.gov
Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a
standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination …
standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination …
A perspective on modelling hepatitis C virus infection
By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of
interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have …
interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have …